Homepage Top Section2

This approval marks a significant milestone as TIVDAK becomes the first antibody-drug conjugate (ADC) with proven overall survival data to receive such endorsement in this patient group. The

RAG-01 is a new therapy aimed at treating non-muscle invasive bladder cancer (NMIBC). This regulatory milestone enables the commencement of clinical trials in the US. NMIBC accounts for

As part of the new collaboration, the two companies will work together to co-create the candidate for the oncology target, leveraging PepMetics technology.  Once the development candidate is

This acceptance will allow GSK to potentially expand the use of Jemperli for the treatment of primary advanced or recurrent endometrial cancer in all the adult patients, including

As part of this strategic partnership, the two companies aim to leverage their shared technology as well as clinical development resources to create synergies in therapeutics development.  The

The deal, valued at up to $380m, includes upfront and milestone payments. Under the terms of the agreement, Cellares will streamline, automate, and transfer technology for selected BMS

This partnership follows the US Food and Drug Administration’s approval of ADSTILADRIN in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)

A product of BioCryst Pharmaceuticals, Orladeyo’s registration, commercialisation and distribution are solely handled by Pint Pharma in Latin America. Hereditary angioedema (HAE) is a genetic disorder characterised by

The designation is specifically for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). TLX101-CDx is a PET imaging agent that targets membrane transport proteins